155 related articles for article (PubMed ID: 24570834)
1. 8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats.
Sharifi H; Mohajjel Nayebi A; Farajnia S
Iran J Basic Med Sci; 2013 Dec; 16(12):1270-5. PubMed ID: 24570834
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats.
Haddadi R; Mohajjel Nayebi A; Brooshghalan SE
Neurosci Lett; 2013 Oct; 555():106-11. PubMed ID: 24045063
[TBL] [Abstract][Full Text] [Related]
3. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats.
Nayebi AM; Rad SR; Saberian M; Azimzadeh S; Samini M
Pharmacol Rep; 2010; 62(2):258-64. PubMed ID: 20508280
[TBL] [Abstract][Full Text] [Related]
4. Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
Sharifi H; Nayebi AM; Farajnia S; Haddadi R
Drug Res (Stuttg); 2015 Aug; 65(8):393-7. PubMed ID: 24782287
[TBL] [Abstract][Full Text] [Related]
5. Role of 5-Hydroxytryptamine 1A Receptors in 6-Hydroxydopmaine-induced Catalepsy-like Immobilization in Rats: a Therapeutic Approach for Treating Catalepsy of Parkinson's Disease.
Eyhani-Rad S; Mohajjel Nayebi A; Mahmoudi J; Samini M; Babapour V
Iran J Pharm Res; 2012; 11(4):1175-81. PubMed ID: 24250551
[TBL] [Abstract][Full Text] [Related]
6. Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors.
Sharifi H; Mohajjel Nayebia A; Farajnia S
Adv Pharm Bull; 2013; 3(1):203-6. PubMed ID: 24312836
[TBL] [Abstract][Full Text] [Related]
7. Serotonin 1A receptor agonist modulation of motor deficits and cortical oscillations by NMDA receptor interaction in parkinsonian rats.
Jiang X; Liang P; Wang K; Jia J; Wang X
Neuropharmacology; 2022 Feb; 203():108881. PubMed ID: 34785162
[TBL] [Abstract][Full Text] [Related]
8. Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.
Prinssen EP; Koek W; Colpaert FC; Kleven MS
Behav Pharmacol; 2000 Jun; 11(3-4):299-305. PubMed ID: 11103884
[TBL] [Abstract][Full Text] [Related]
9. Effect of Buspirone, Fluoxetine and 8-OH-DPAT on Striatal Expression of Bax, Caspase-3 and Bcl-2 Proteins in 6-Hydroxydopamine-Induced Hemi-Parkinsonian Rats.
Sharifi H; Mohajjel Nayebi A; Farajnia S; Haddadi R
Adv Pharm Bull; 2015 Nov; 5(4):491-5. PubMed ID: 26819921
[TBL] [Abstract][Full Text] [Related]
10. Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc.
Haddadi R; Poursina M; Zeraati F; Nadi F
Inflammopharmacology; 2018 Oct; 26(5):1305-1316. PubMed ID: 29616453
[TBL] [Abstract][Full Text] [Related]
11. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
Ninan I; Kulkarni SK
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
[TBL] [Abstract][Full Text] [Related]
12. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Mahmoudi J; Nayebi AM; Samini M; Reyhani-Rad S; Babapour V
Pharmacol Rep; 2011; 63(4):908-14. PubMed ID: 22001978
[TBL] [Abstract][Full Text] [Related]
13. Fluoxetine improves the effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats.
Mahmoudi J; Mohajjel Nayebi A; Reyhani-Rad S; Samini M
Adv Pharm Bull; 2012; 2(2):149-55. PubMed ID: 24312786
[TBL] [Abstract][Full Text] [Related]
14. Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.
Andersen HL; Kilpatrick IC
Br J Pharmacol; 1996 May; 118(2):421-7. PubMed ID: 8735647
[TBL] [Abstract][Full Text] [Related]
15. The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats.
Sharifi H; Mohajjel Nayebia A; Farajnia S
Adv Pharm Bull; 2012; 2(1):127-31. PubMed ID: 24312782
[TBL] [Abstract][Full Text] [Related]
16. Effect of WR-1065 on 6-hydroxydopamine-induced catalepsy and IL-6 level in rats.
Kheradmand A; Nayebi AM; Jorjani M; Haddadi R
Iran J Basic Med Sci; 2016 May; 19(5):490-6. PubMed ID: 27403255
[TBL] [Abstract][Full Text] [Related]
17. Short-Term Treatment with Silymarin Improved 6-OHDA-Induced Catalepsy and Motor Imbalance in Hemi-Parkisonian Rats.
Haddadi R; Eyvari Brooshghalan S; Farajniya S; Mohajjel Nayebi A; Sharifi H
Adv Pharm Bull; 2015 Nov; 5(4):463-9. PubMed ID: 26819917
[TBL] [Abstract][Full Text] [Related]
18. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release.
Lucas G; Bonhomme N; De Deurwaerdère P; Le Moal M; Spampinato U
Psychopharmacology (Berl); 1997 May; 131(1):57-63. PubMed ID: 9181636
[TBL] [Abstract][Full Text] [Related]
19. Decreased response of interneurons in the medial prefrontal cortex to 5-HT₁A receptor activation in the rat 6-hydroxydopamine Parkinson model.
Zhang Q; Wang S; Zhang L; Zhang H; Qiao H; Niu X; Liu J
Neurol Sci; 2014 Aug; 35(8):1181-7. PubMed ID: 24563117
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy.
Wadenberg ML; Ahlenius S
J Neural Transm Gen Sect; 1991; 83(1-2):43-53. PubMed ID: 1673344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
